• pat50
    Amazing not a single word on CNBC, analyst comment, ect on SSKN's FDA approval or EU approval. Market cap of 100mil is still cheap.
    Reply (2)
    • pat50: This company really needs some market coverage-all the bears who are short rule the chatter.
    • jrusso9722: Hi pat50, Yes, I agree. Saving lives is the issue. Shorters will eat their shorts. MelaFind will save lives---non invasively.